Despite pharmacy benefit managers posting slow drug spending growth in 2017, patients and employers are still carrying a tremendous amount of cost burden, National Pharmaceutical Council President Dan Leonard says.
PBM Prime Therapeutics also brought down costs year over year.
“Unfortunately, from the patient standpoint, things look less rosy,” Leonard writes in an article on Chain Drug Review. “In 2016, the last years for which figures are available, out-of-pocket spending by consumers was at the highest level in a decade, and that figure isn’t expected to slow. Patients are shouldering ore of the burden, even as PBMs hold down prices.